Screener
4D Molecular Therapeutics FDMT Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(68,760) | $(47,972) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 4,453 | 6,986 |
| Change in fair value of derivative liability | 12 | (88) |
| Depreciation and amortization | 1,269 | 1,051 |
| Amortization of right-of-use assets | 786 | 703 |
| Net accretion of discount on marketable securities | (1,134) | (1,267) |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's stock-based comp?
- 4D Molecular Therapeutics (FDMT) reported stock-based comp of $4.45M in Q1 2026.
- How has 4D Molecular Therapeutics's stock-based comp changed year-over-year?
- 4D Molecular Therapeutics's stock-based comp decreased by 36.3% year-over-year, from $6.99M to $4.45M.
- What is the long-term trend for 4D Molecular Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's stock-based comp has grown at a 12.4% compound annual growth rate (CAGR), from $13.8M to $22.02M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about 4D Molecular Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude